Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

PROSCA BLADDR 2021 | Highlights from PROSCA/BLADDR 2021

Robert Jones • 15 Oct 2021
PROSCA BLADDR 2021
Bladder Cancer Genitourinary Cancer

Robert Jones, MD, PhD, University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, discusses highlights from the BLADDR 2021 meeting, including multidisciplinary aspects, as well as patient representation at this meeting. This interview took place at the PROSCA/BLADDR 2021 congress.

More from Robert Jones

Areas of unmet need in metastatic urothelial carcinoma
2:04
Areas of unmet need in metastatic urothelial carcinoma
Robert Jones • 4 Jun 2022
ASCO 2022: genitourinary cancer highlights
1:10
ASCO 2022: genitourinary cancer highlights
Robert Jones • 4 Jun 2022
Replacing the current standard of care for urothelial carcinoma
0:58
Replacing the current standard of care for urothelial carcinoma
Robert Jones • 4 Jun 2022
Final results from ATLANTIS cabozantinib arm for urothelial carcinoma
2:19
Final results from ATLANTIS cabozantinib arm for urothelial carcinoma
Robert Jones • 4 Jun 2022

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals